Mesoblast Limited

Income statement, core metrics (chartable)

Sources by year:

• FY2022–FY2023: FY2023 20-F and results release.

• FY2024: FY2024 results release (StockTitan, Moomoo transcription).

• FY2025–FY2026: FY2026 6-K income statement.

Notes:

• Net margins are derived.

• The FY2024 release restates FY2023 EPS as -10.53 US cents, against -11.08 in the FY2023 release. This is likely a weighted-share or presentation difference; both figures are noted.

Income statement, extended detail (partial disclosure)

"n/d" means not disclosed in the sources retrieved; "n/a" means not applicable.

Presentation change. From FY2025 the income statement presents R&D and SG&A only. Manufacturing costs are allocated to R&D (product development) and cost of revenue. FY2022–FY2023 figures are therefore not like-for-like with FY2025–FY2026.

FY2025 R&D distortion. FY2025 R&D was flattered by a US$23.0 million inventory benefit: pre-launch manufacturing costs previously expensed were capitalised at approval. Adjusted for this, FY2026 R&D rose by US$39.7 million, made up of:

• US$17.3 million of product development (both platforms);

• US$21.2 million of Phase 3 trials and regulatory filings.

Margin profile

Revenue CAGR.

• FY2022–FY2026: +85.3% (derived; US$10.2 million to US$120.3 million over four years).

• FY2023–FY2026 (three years): +152.3% (derived).

Balance sheet

Cash sources: FY2022 (FY2022 release), FY2023 (FY2023 release), FY2024 (Wikipedia and FY2025 cash flow opening balance of US$62.96 million; the FY2024 release quoted US$63.3 million, a minor discrepancy), FY2025–FY2026 (FY2026 balance sheet).

FY2025–FY2026 balance sheet detail (chartable)

A negative net debt figure means net cash.

Intangibles detail (FY2026 20-F). In-process R&D acquired totals US$325.1 million:

• Cardiovascular products: US$254.4 million.

• Intravenous products for metabolic diseases and inflammatory/immunologic conditions: US$70.7 million.

The marketed-product intangible for Ryoncil (US$102.7 million reclassified in December 2024) is amortised straight-line over 21 years. The goodwill sub-total is not separately verified.

Cash flow

Sources: FY2022–FY2024 results releases; FY2025–FY2026 cash flow statement.

FY2025–FY2026 cash flow detail (chartable)

Intra-year trajectory. FY2026 H2 operating cash spend was only US$13.4 million, against US$50 million in the prior-year comparable half. The March 2026 quarter spend was US$4.1 million. This puts Mesoblast close to operating cash-flow breakeven on a run-rate basis, before the FY2027 increase in Phase 3 and manufacturing spend.

Interest paid. Cash interest jumped to US$17.8 million in FY2026 because accrued interest and royalty-linked amounts were settled when the Oaktree and NovaQuest facilities were retired. The new facility costs about US$10 million a year (US$125 million at 8%).

Ratios

"n/m" means not meaningful.

Commentary on trends, inflections and drivers

1. Revenue inflection (FY2025–FY2026).

• From FY2022 to FY2024, revenue fell from US$10.2 million to about US$5.9 million. It was pure royalty income, eroded by yen depreciation (US$1.0 million of the FY2023 decline was foreign exchange) and the loss of milestone income.

• After approval, revenue rose sevenfold in FY2026 to US$120.3 million.

• Management's FY2026 guidance of US$110–120 million of Ryoncil net revenue (February 2026) was met at US$115.2 million, near the midpoint. This is an important credibility marker for a management team historically associated with regulatory delays.

2. Gross margin structure.

• Gross margin excluding amortization is above 90%, which is unusually high for a cell therapy.

• This reflects allogeneic, off-the-shelf economics: one donor yields thousands of doses, against the patient-specific manufacturing of autologous CAR-T therapies.

• Amortization of the Ryoncil intangible (US$6.1 million in FY2026) is the main gap between reported and underlying gross margin.

3. Operating cost re-acceleration is deliberate.

• R&D more than doubled on a reported basis, because Phase 3 CLBP enrolment, the adult GvHD trial start, BLA preparation for REVASCOR and manufacturing for BLA lots all hit the year.

• SG&A rose about US$18 million for the US launch infrastructure.

4. Below-the-line noise.

• Contingent-consideration remeasurements (linked to future payments to former Osiris and other sellers) swung from -US$14.9 million to +US$12.1 million, a US$27 million year-on-year swing. This explains a large part of the net-loss improvement.

• Underlying operating loss excluding these remeasurements improved more modestly, from US$58.9 million to US$46.0 million (derived).

5. Capital structure.

• Mesoblast moved from net cash of about US$40 million (FY2025, after the January 2025 placement) to modest net debt of about US$16 million (FY2026).

• The debt itself is now cheaper (8% fixed against higher-cost Oaktree and NovaQuest instruments), interest-only to December 2030, and secured only by the TEMCELL royalty.

• Management states that cash plus Ryoncil cash generation is sufficient for the next 12 months, and the going-concern basis is supported. The 20-F still flags that funding beyond 12 months may need partnerships or capital.

Management guidance

• No numeric FY2027 guidance was identified.

• Management expects continued Ryoncil growth and has signalled an ambition to "double net revenues" (R&D Day).

• Spending priorities are Phase 3 programmes, manufacturing for BLA lots and commercial inventory, and continued progress toward profitability.

Consensus expectations

No full consensus revenue or EPS was verified. Aggregators (Alphaspread) imply very high multi-year revenue CAGRs, driven by CLBP and adult GvHD optionality.

Bull case

1. Durable, high-margin cash engine. US$115 million of first-year Ryoncil revenue at about 91% underlying gross margin, with H2 cash burn of US$13.4 million, means the base business can largely self-fund. Adult second-line plus third-line SR-aGvHD (about 3× the pediatric market) could multiply Ryoncil sales from 2028.

2. CLBP is a mispriced binary. A positive 12-month readout in a 350-patient, well-powered trial would open a market above US$10 billion with an RMAT-designated product and an FDA-confirmed path. At an EV of about US$2 billion, the market is assigning modest probability-weighted value.

3. De-risked balance sheet and CMC. 8% interest-only debt to 2030, all US assets unencumbered for partnering, and FDA approval of TIBA reduce financing and manufacturing tail risks that historically dominated the story.

Bear case

1. Pediatric ceiling and quarterly volatility. Pediatric SR-aGvHD is a small orphan population, and quarterly net revenue moved from about US$30 million (December, net-equivalent) to US$30.3 million (March) to US$36 million (June). Growth may plateau before adult data arrive in late 2027.

2. Binary clinical risk with a mixed track record. DREAM-HF missed its primary endpoint, the earlier CLBP study did not deliver registrational success, and the company received two CRLs. A CLBP failure in 2027 would remove the largest part of the long-term thesis.

3. Concentration and governance. About 96% of revenue comes from one product made at one third-party site, and the sole lender is the largest shareholder and a director. Receivables (US$57.7 million) and inventory (US$28.1 million) are rising faster than cash collection.

Key catalysts and monitorables (next 12 months)

Concluding analyst verdict

Mesoblast has done what many skeptics thought it never would. It secured the first FDA approval for an MSC therapy and turned it, within 15 months, into a US$115 million product with gross margins above 90% and a near-breakeven second-half cash burn. FY2026 marks a real regime change: the debate is no longer about whether the platform can be approved and manufactured to FDA standards, but about how large the franchise can become.

The quality of the FY2026 print is mixed but improving. Revenue met guidance. Operating cash burn fell to US$43.8 million for the year and US$13.4 million in the second half. The refinancing replaced costly structured debt with an 8% interest-only facility secured only by a legacy royalty.

Against that, a US$27 million swing in non-cash contingent-consideration remeasurements flatters the headline improvement in net loss. Working capital is absorbing cash. Revenue remains concentrated in one pediatric orphan indication made at one contract site.

At an enterprise value of about US$2.0 billion (about 17× FY2026 sales), the market is paying for growth beyond the pediatric label but not for full pipeline success. That seems broadly rational. Two binary readouts in 2027 will define the next valuation leg:

• adult SR-aGvHD, with an interim analysis in Q4 CY2027;

• CLBP, with top-line data in mid/H2 CY2027.

Management's credibility on timelines, historically its main weakness, has improved through 2026: guidance was met, enrolment targets were beaten, and the potency assay was approved.

Verdict: a constructive but high-variance profile. The commercial base and balance sheet now give Mesoblast enough runway to reach its 2027 catalysts without forced dilution. That is a material change from its history.

Investors should track Ryoncil quarterly net revenue (sustained growth above about US$36 million per quarter), receivables collection, progress toward a second manufacturing site, and governance around the related-party lender. The risk-reward is asymmetric toward the CLBP outcome. Position sizing should reflect a meaningful probability of trial failure, given the company's mixed history in randomised studies.

---

End of dossier. All figures in US dollars unless stated. "n/d" means not disclosed in sources reviewed; "n/m" means not meaningful; "derived" means calculated by the analyst from reported line items. Where sources conflict, both values are noted in the relevant section.